Incretin hormone mimetics and analogues in diabetes therapeutics

被引：83

作者：

Green, Brian D. ^{[1
]}

Flatt, Peter R. ^{[2
]}

机构：

[1] Queens Univ Belfast, Sch Biol Sci, Belfast BT6 0NJ, Antrim, North Ireland

[2] Univ Ulster, Sch Biomed Sci, Coleraine BT52 1SA, Londonderry, North Ireland

来源：

BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM | 2007年 / 21卷 / 04期

关键词：

incretin; glucagon-like peptide-1; glucose-dependent insulinotropic polypeptide; insulin; type-2; diabetes; glucose homeostasis; exendin;

D O I：

10.1016/j.beem.2007.09.003

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The incretin hormones glucagon-like peptide-I (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are physiological gut peptides with insulin-releasing and extrapancreatic glucoregulatory actions. Incretin analogues/mimetics activate GLP-I or GIP receptors whilst avoiding physiological inactivation by dipeptidyl peptidase 4 (DPP-4), and they represent one of the newest classes of antidiabetic drug. The first clinically approved GLP-1 mimetic for the treatment of type-2 diabetes is exenatide (Byetta/exendin) which is administered subcutaneously twice daily. Clinical trials of liraglutide, a GLP-1 analogue suitable for once-daily administration, are ongoing. A number of other incretin molecules are at earlier stages of development. This review discusses the various attributes of GLP-1 and GIP for diabetes treatment and summarises current clinical data. Additionally, it explores the therapeutic possibilities offered by preclinical agents, such as non-peptide GLP-1 mimetics, GLP-1/glucagon hybrid peptides, and specific GIP receptor antagonists.

引用

页码：497 / 516

页数：20

共 107 条

[71] Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats [J].

Lynn, FC ;

Pamir, N ;

Ng, EHC ;

McIntosh, CHS ;

Kieffer, TJ ;

Pederson, RA .

DIABETES, 2001, 50 (05) :1004-1011

[72] Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211) A 12-week, double-blind, randomized, controlled trial [J].

Madsbad, S ;

Schmitz, O ;

Ranstam, J ;

Jakobsen, G ;

Matthews, DR .

DIABETES CARE, 2004, 27 (06) :1335-1342

[73] A stable analogue of glucose-dependent insulinotropic polypeptide, GIP(LysPAL16), enhances functional differentiation of mouse embryonic stem cells into cells expressing islet-specific genes and hormones [J].

Marenah, Lamin ;

McCluskey, Jane T. ;

Abdel-Wahab, Yasser H. A. ;

O'Harte, Finbarr P. M. ;

McClenaghan, Neville H. ;

Flatt, Peter R. .

BIOLOGICAL CHEMISTRY, 2006, 387 (07) :941-947

[74] EFFECT OF GASTRIC-INHIBITORY POLYPEPTIDE ON PENTAGASTRIN-STIMULATED ACID-SECRETION IN MAN [J].

MAXWELL, V ;

SHULKES, A ;

BROWN, JC ;

SOLOMON, TE ;

WALSH, JH ;

GROSSMAN, MI .

DIGESTIVE DISEASES AND SCIENCES, 1980, 25 (02) :113-116

[75] Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects [J].

Meier, JJ ;

Gallwitz, B ;

Kask, B ;

Deacon, CF ;

Holst, JJ ;

Schmidt, WE ;

Nauck, MA .

DIABETES, 2004, 53 :S220-S224

[76] Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects [J].

Meier, JJ ;

Nauck, MA ;

Siepmann, N ;

Greulich, M ;

Holst, JJ ;

Deacon, CF ;

Schmidt, WE ;

Gallwitz, B .

METABOLISM-CLINICAL AND EXPERIMENTAL, 2003, 52 (12) :1579-1585

[77] THE EFFECT OF GLYBURIDE ON BETA-CELL SENSITIVITY TO GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE [J].

MENEILLY, GS ;

BRYERASH, M ;

ELAHI, D .

DIABETES CARE, 1993, 16 (01) :110-114

[78] Inhibition of gastric inhibitory polypeptide signaling prevents obesity [J].

Miyawaki, K ;

Yamada, Y ;

Ban, N ;

Ihara, Y ;

Tsukiyama, K ;

Zhou, HY ;

Fujimoto, S ;

Oku, A ;

Tsuda, K ;

Toyokuni, S ;

Hiai, H ;

Mizunoya, W ;

Fushiki, T ;

Holst, JJ ;

Makino, M ;

Tashita, A ;

Kobara, Y ;

Tsubamoto, Y ;

Jinnouchi, T ;

Jomori, T ;

Seino, Y .

NATURE MEDICINE, 2002, 8 (07) :738-742

[79] REDUCED INCRETIN EFFECT IN TYPE-2 (NON-INSULIN-DEPENDENT) DIABETES [J].

NAUCK, M ;

STOCKMANN, F ;

EBERT, R ;

CREUTZFELDT, W .

DIABETOLOGIA, 1986, 29 (01) :46-52

[80] Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes [J].

Nauck, M. A. ;

Hompesch, M. ;

Filipczak, R. ;

Le, T. D. T. ;

Zdravkovic, M. ;

Gumprecht, J. .

EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2006, 114 (08) :417-423

← 2 3 4 5 6 7 8 9 10 11 →